TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30703444

Group type: EXPERIMENTAL
Intervention: Single dose of 100 mg moguisteine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single dose of 200 mg moguisteine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Single dose of 400 mg moguisteine
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Multiple doses of 200 mg moguisteine (three times daily for five consecutive days)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Safety assessment
Number of subjects: 12
Study: 27130976

Group type: EXPERIMENTAL
Intervention: 250 Hz ablation frequency
Number of subjects: 28

Group type: COMPARATOR
Intervention: 500 Hz ablation frequency
Number of subjects: 28
Study: 25922190

Group type: EXPERIMENTAL
Intervention: Granulocyte macrophage colony stimulating factor (GM‐CSF)
Number of subjects: 280

Group type: COMPARATOR
Intervention: Control
Number of subjects: 280
Study: 24130357

Group type: EXPERIMENTAL
Intervention: Custom-made footwear with improved offloading (∼20% peak pressure relief)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care (nonimproved custom-made footwear)
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Custom-made footwear with improved offloading (in patients with high adherence)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Usual care (in patients with high adherence)
Number of subjects: 171
Study: 21362469

Group type: EXPERIMENTAL
Intervention: 2 h running at 60% V O(2peak) (EX)
Number of subjects: 32

Group type: COMPARATOR
Intervention: 2 h seated rest (CON)
Number of subjects: 32
Study: 19373517

Group type: EXPERIMENTAL
Intervention: Intensive tobacco‐dependence intervention based on self‐determination theory (SDT)
Number of subjects: 1006

Group type: COMPARATOR
Intervention: Community care participants received cessation pamphlets and information on local treatment programs
Number of subjects: 1006
Study: 16720024

Group type: EXPERIMENTAL
Intervention: ACE-defined MetS
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: MetS defined by five definitions
Number of subjects: 541

Group type: COMPARATOR
Intervention: None of the five definitions
Number of subjects: 541
Study: 15546073

Group type: EXPERIMENTAL
Intervention: Micafungin 50 mg (1 mg/kg for patients weighing <50 kg)
Number of subjects: 882

Group type: COMPARATOR
Intervention: Fluconazole 400 mg (8 mg/kg for patients weighing <50 kg)
Number of subjects: 882
Study: 11444499

Group type: EXPERIMENTAL
Intervention: Nicorandil (0.1 mg/kg) administered during cardiopulmonary bypass
Number of subjects: 70

Group type: COMPARATOR
Intervention: No nicorandil (control group)
Number of subjects: 70
Study: 9924680

Group type: EXPERIMENTAL
Intervention: Four sessions per week
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Two sessions per week
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 20
Study: 7997395

Group type: EXPERIMENTAL
Intervention: Digoxin tablets
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Digoxin capsules
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (tablets)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control (capsules)
Number of subjects: 6
Study: 29373382

Group type: EXPERIMENTAL
Intervention: Mannequin-based simulation
Number of subjects: 84

Group type: COMPARATOR
Intervention: Virtual simulation
Number of subjects: 84
Study: 26764884

Group type: EXPERIMENTAL
Intervention: Sofosbuvir therapy with peginterferon and ribavirin
Number of subjects: 600

Group type: COMPARATOR
Intervention: Peginterferon and ribavirin only
Number of subjects: 600
Study: 24862701

Group type: EXPERIMENTAL
Intervention: 4% articaine
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2% lidocaine
Number of subjects: 100
Study: 23252003

Group type: EXPERIMENTAL
Intervention: HTESB therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 40
Study: 20521323

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19008269

Group type: EXPERIMENTAL
Intervention: Recruitment strategies including named coordinating centre staff, prompt identification and resolution of logistic problems, varying volume of invitations, using local non‐attendance rates, and organizing large ad hoc clinics.
Number of subjects: 202638

Group type: EXPERIMENTAL
Intervention: Trial management and planning strategies.
Number of subjects: 202638

Group type: EXPERIMENTAL
Intervention: Invitation to participate in the trial.
Number of subjects: 202638

Group type: EXPERIMENTAL
Intervention: Appointment scheduling for recruitment.
Number of subjects: 202638
Study: 17183628

Group type: EXPERIMENTAL
Intervention: Potent antiretroviral therapy (ART)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Higher pretreatment HIV-1 RNA levels
Number of subjects: 101
Study: 14504915

Group type: EXPERIMENTAL
Intervention: 7.5 mg/week of methotrexate
Number of subjects: 46

Group type: COMPARATOR
Intervention: 2 g/day of sulphasalazine
Number of subjects: 46
Study: 10714732

Group type: EXPERIMENTAL
Intervention: Real bipolar permanent magnets
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham bipolar permanent magnets
Number of subjects: 20
Study: 9186834

Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation
Number of subjects: 77

Group type: COMPARATOR
Intervention: Endoscopic injection sclerotherapy
Number of subjects: 77
Study: 8232869

Group type: EXPERIMENTAL
Intervention: 22 G needle
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: 25 G needle
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Sex
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Myelogram type
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Myelographer
Number of subjects: 113
Study: 3986068

Group type: EXPERIMENTAL
Intervention: Extradural analgesia (local anaesthetics from before skin incision until 24 h after skin incision plus extradural morphine 4 mg every 12 h from 3 h to 72 h after skin incision)
Number of subjects: 20

Group type: COMPARATOR
Intervention: General anaesthesia with low‐dose fentanyl plus intermittent systemic morphine for postoperative pain
Number of subjects: 20
Study: 31295161

Group type: EXPERIMENTAL
Intervention: Prucalopride 2 mg q.d. for 4 weeks
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30328976

Group type: EXPERIMENTAL
Intervention: Infusion pump A at 100 mL/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion pump A at 300 mL/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion pump B at 100 mL/h
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Infusion pump B at 300 mL/h
Number of subjects: 0
Study: 26947800

Group type: EXPERIMENTAL
Intervention: EDACS‐ADP
Number of subjects: 558

Group type: COMPARATOR
Intervention: ADAPT‐ADP
Number of subjects: 558

Group type: EXPERIMENTAL
Intervention: Both pathways
Number of subjects: 558
Study: 24606836

Group type: EXPERIMENTAL
Intervention: MCA and IRT (LLRA model)
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: PCA
Number of subjects: 381
Study: 21614461

Group type: EXPERIMENTAL
Intervention: Rinse A (experimental amine fluoride/stannous fluoride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rinse B (experimental amine fluoride/stannous fluoride)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rinse C (phenolic/essential oil rinse)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rinse D (negative control, water rinse)
Number of subjects: 0
Study: 20177360

Group type: EXPERIMENTAL
Intervention: AIDS events
Number of subjects: 9583

Group type: EXPERIMENTAL
Intervention: Serious non-AIDS (SNA) events
Number of subjects: 9583
Study: 17604892

Group type: EXPERIMENTAL
Intervention: Intervention group (participation in a 4 month programme of intergenerational activities)
Number of subjects: 519

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 519
Study: 15601806

Group type: EXPERIMENTAL
Intervention: Recombinant human albumin (rHA)
Number of subjects: 530

Group type: COMPARATOR
Intervention: Human serum albumin (HSA)
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Intravenous administration of rHA
Number of subjects: 530

Group type: COMPARATOR
Intervention: Intravenous administration of HSA
Number of subjects: 530

Group type: EXPERIMENTAL
Intervention: Recombinant human albumin (rHA) and Human serum albumin (HSA)
Number of subjects: 530
Study: 12189224

Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 10457510

Group type: EXPERIMENTAL
Intervention: Males: 70-lb bench press, standing long jump, and agility
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Females: Agility and 1.5-mile endurance run
Number of subjects: 48

Group type: COMPARATOR
Intervention: Males: Agility
Number of subjects: 48
Study: 7794983

Group type: EXPERIMENTAL
Intervention: Community-based arthritis education program (6 weekly sessions of 2.5 hours' duration)
Number of subjects: 175

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 175
Study: 2130666

Group type: EXPERIMENTAL
Intervention: GM1 ganglioside treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 376054

Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg daily for six weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Carbenoxolone sodium 300 mg daily for one week then 150 mg daily for five weeks
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cimetidine
Number of subjects: 54

Group type: COMPARATOR
Intervention: Carbenoxolone sodium
Number of subjects: 54
Study: 31112957

Group type: EXPERIMENTAL
Intervention: Levofloxacin (500 mg per day for 4 weeks)
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Levofloxacin combined with azithromycin
Number of subjects: 2500

Group type: EXPERIMENTAL
Intervention: Levofloxacin and azithromycin combination
Number of subjects: 2500
Study: 28068121

Group type: EXPERIMENTAL
Intervention: Culturally adapted Motivational Enhancement Therapy delivered in Spanish
Number of subjects: 405
Study: 25807939

Group type: EXPERIMENTAL
Intervention: 5 mg daily dose of delayed-release prednisone
Number of subjects: 350

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 350
Study: 24516413

Group type: EXPERIMENTAL
Intervention: Actovegin (2,000 mg/day for up to 20 intravenous infusions followed by 1,200 mg/day orally)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 500
Study: 21414452

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Psychoeducational (PE) seminar
Number of subjects: 69
Study: 20136957

Group type: EXPERIMENTAL
Intervention: Wire-guided cannulation (WGC)
Number of subjects: 1413

Group type: COMPARATOR
Intervention: Conventional contrast-assisted cannulation
Number of subjects: 1413
Study: 18037817

Group type: EXPERIMENTAL
Intervention: Duloxetine (40, 60, 80, 120 mg/day)
Number of subjects: 2463

Group type: COMPARATOR
Intervention: SSRIs (10 mg/day escitalopram, 20 mg/day fluoxetine and paroxetine)
Number of subjects: 2463

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 2463
Study: 15239013

Group type: EXPERIMENTAL
Intervention: Heterologous threaded cylindrical bone (Unilab Surgibone)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Titanium implant (Bak‐C; Spine‐Tech, Minneapolis)
Number of subjects: 44
Study: 10958599

Group type: EXPERIMENTAL
Intervention: Amifostine (910 mg/m2) given as a short infusion prior to cisplatin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no amifostine)
Number of subjects: 31
Study: 9048415

Group type: EXPERIMENTAL
Intervention: 5‐min audiotaped persuasive message about BBTD
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Same audiotaped message with overheard audience response affirming the message
Number of subjects: 120

Group type: COMPARATOR
Intervention: No intervention control group
Number of subjects: 120
Study: 7687940

Group type: EXPERIMENTAL
Intervention: Simple elastic knee sleeve
Number of subjects: 84

Group type: COMPARATOR
Intervention: Elastic knee sleeve with silicone patellar ring
Number of subjects: 84

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 84
Study: 3576126

Group type: EXPERIMENTAL
Intervention: Omeprazole (80 mg)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 30285503

Group type: EXPERIMENTAL
Intervention: Bang Pre‐Workout Master Blaster (BMB)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 10
Study: 31564137

Group type: EXPERIMENTAL
Intervention: Transcatheter mitral valve repair (TMVr)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT)
Number of subjects: 0
Study: 28157653

Group type: EXPERIMENTAL
Intervention: Suppository + vaginal cream + oral vitamin B complex (group C)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Suppository + oral antifungal agents (group A)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Suppository + vaginal cream (group B)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Vitamin B complex (various dosages in mice)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Fluconazole (in vitro with vitamin B complex)
Number of subjects: 158
Study: 26446482

Group type: EXPERIMENTAL
Intervention: High-dose soy (HDS) - 2 soy muffins containing 25 g soy protein
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: Low-dose soy (LDS) - 1 soy and 1 wheat muffin containing 12.5 g soy protein and 12.5 g whey protein
Number of subjects: 243

Group type: COMPARATOR
Intervention: Control - 2 wheat muffins containing 25 g whey protein
Number of subjects: 243

Group type: EXPERIMENTAL
Intervention: All groups (HDS, LDS, Control)
Number of subjects: 243
Study: 24026038

Group type: EXPERIMENTAL
Intervention: Olmesartan (n = 280)
Number of subjects: 563

Group type: COMPARATOR
Intervention: Placebo (n = 283)
Number of subjects: 563
Study: 21670457

Group type: EXPERIMENTAL
Intervention: Intramuscular injection of depot hydroxyprogesterone 500 mg 5 to 14 days before surgery
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Control group (surgery only)
Number of subjects: 1000
Study: 18814804

Group type: EXPERIMENTAL
Intervention: High-fat modified sham feeding (MSF)
Number of subjects: 14
Study: 17098421

Group type: EXPERIMENTAL
Intervention: pviFOX (oxaliplatin plus protracted infusion of 5‐fluorouracil)
Number of subjects: 118

Group type: COMPARATOR
Intervention: XELOX (oxaliplatin plus capecitabine)
Number of subjects: 118
Study: 15301775

Group type: EXPERIMENTAL
Intervention: Non-copers
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Copers
Number of subjects: 3

Group type: COMPARATOR
Intervention: Uninjured subjects
Number of subjects: 3
Study: 11294041

Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Mianserin (30 mg/day)
Number of subjects: 116
Study: 9447285

Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol diphosphate (DES‐DP)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (LH‐RH agonist: LHRH‐A)
Number of subjects: 36
Study: 7940142

Group type: EXPERIMENTAL
Intervention: 2% epinephrine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 4% pilocarpine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 0.5% timolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1% p‐amino‐clonidine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Exercise in normal volunteers
Number of subjects: 0

Group type: COMPARATOR
Intervention: OHT subjects (compared to normal controls)
Number of subjects: 0

Group type: COMPARATOR
Intervention: LTG and RD subjects (compared to normal controls)
Number of subjects: 0
Study: 3344599

Group type: EXPERIMENTAL
Intervention: Butorphanol
Number of subjects: 12

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 12
Study: 29689636

Group type: EXPERIMENTAL
Intervention: HIFU started 1 minute after SonoVue injection
Number of subjects: 102

Group type: COMPARATOR
Intervention: HIFU started 10 minutes after SonoVue injection
Number of subjects: 102
Study: 27704865

Group type: EXPERIMENTAL
Intervention: Ayurvedic massage (Sahacharadi Taila) for 2 weeks (6 hours total)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Local thermal therapy for 2 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ayurvedic massage (Sahacharadi Taila)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Local thermal therapy
Number of subjects: 64
Study: 26759297

Group type: EXPERIMENTAL
Intervention: 65 µm glycine powder air-polishing (GPAP)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Ultrasonic scaling
Number of subjects: 23
Study: 24294709

Group type: EXPERIMENTAL
Intervention: Blunt surgical needles
Number of subjects: 240

Group type: COMPARATOR
Intervention: Sharp surgical needles
Number of subjects: 240
Study: 21711204

Group type: EXPERIMENTAL
Intervention: 1600 mg Avena sativa herb extract
Number of subjects: 36

Group type: COMPARATOR
Intervention: 0 mg Avena sativa herb extract
Number of subjects: 36

Group type: COMPARATOR
Intervention: 2400 mg Avena sativa herb extract
Number of subjects: 36
Study: 19704269

Group type: EXPERIMENTAL
Intervention: Negative pressure wound therapy (NPWT)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control group (standard fine mesh gauze dressing)
Number of subjects: 59
Study: 16923836

Group type: EXPERIMENTAL
Intervention: Experimental Web site providing educational material about organ donation and transplantation
Number of subjects: 490

Group type: COMPARATOR
Intervention: Control Web site providing educational material on methods to avoid the common cold
Number of subjects: 490
Study: 15558393

Group type: EXPERIMENTAL
Intervention: 9-month, twice-weekly exercise program (n = 11)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Non-exercising controls (n = 10)
Number of subjects: 21
Study: 11375232

Group type: EXPERIMENTAL
Intervention: Clinical guidelines disseminated to general practices in the intervention arm.
Number of subjects: 689

Group type: COMPARATOR
Intervention: Control practices that received clinical guidelines one year later.
Number of subjects: 689
Study: 9236555

Group type: EXPERIMENTAL
Intervention: Intramuscular immune serum globulin (4 mL of 16% polyvalent immune serum globulin every 2 months, n = 450)
Number of subjects: 899

Group type: COMPARATOR
Intervention: Placebo (n = 449)
Number of subjects: 899
Study: 8353585

Group type: EXPERIMENTAL
Intervention: Arterial line sample with discard volume deadspace
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Arterial line sample with discard volume deadspace + 2 mL
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Arterial line sample with discard volume deadspace + 4 mL
Number of subjects: 30

Group type: COMPARATOR
Intervention: Venous control samples
Number of subjects: 30
Study: 3226848

Group type: EXPERIMENTAL
Intervention: Exercise group (n = 10)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Exercise with cognitive strategy instructions (n = 16)
Number of subjects: 26
Study: 29714501

Group type: EXPERIMENTAL
Intervention: DEsCT with ASIS technique and reduced iodine load (Group B2)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: DEsCT with ASIS technique and reduced iodine load (Group B)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Conventional 120-kVp CT (Group A)
Number of subjects: 62
Study: 27273731

Group type: EXPERIMENTAL
Intervention: Liraglutide (1.8 mg/d)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 71
Study: 26594287

Group type: EXPERIMENTAL
Intervention: Emotional Intelligence (EI) intervention group
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study: 22927665

Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 402

Group type: COMPARATOR
Intervention: CRT-P
Number of subjects: 402
Study: 20628153

Group type: EXPERIMENTAL
Intervention: Bortezomib-melphalan-prednisone (VMP)
Number of subjects: 0
Study: 18977978

Group type: EXPERIMENTAL
Intervention: Barriers to Care Questionnaire scores
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Having a regular doctor
Number of subjects: 252

Group type: EXPERIMENTAL
Intervention: Not having experienced foregone care
Number of subjects: 252
Study: 22338850

Group type: EXPERIMENTAL
Intervention: Flapless technique (FL)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Full-thickness flap technique (FT)
Number of subjects: 9
Study: 15918162

Group type: EXPERIMENTAL
Intervention: Academic detailing
Number of subjects: 356

Group type: COMPARATOR
Intervention: Not receiving academic detailing (Control)
Number of subjects: 356
Study: 12390597

Group type: EXPERIMENTAL
Intervention: Chloroquine (CQ)
Number of subjects: 948

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine (SP)
Number of subjects: 948
Study: 9458325

Group type: EXPERIMENTAL
Intervention: PALA (250 mg/m² on day 1) + FA (20 mg/m²) + 5-FU (400 mg/m², 5 min i.v. bolus injection) on days 2-5
Number of subjects: 6

Group type: COMPARATOR
Intervention: 5-FU (400 mg/m², 5 min i.v. bolus injection) + FA (20 mg/m²) on days 2-5 without PALA
Number of subjects: 6
Study: 7891486

Group type: EXPERIMENTAL
Intervention: Close supervision by nominated key-workers (intervention group)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Standard follow-up from psychiatric and social services (control group)
Number of subjects: 400
Study: 2229705

Group type: EXPERIMENTAL
Intervention: Treatment group (education and psychological support in addition to routine care)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (routine care only)
Number of subjects: 60
Study: 365286

Group type: EXPERIMENTAL
Intervention: Directed masturbation programme
Number of subjects: 35

Group type: COMPARATOR
Intervention: Combined sensate focus and supportive psychotherapeutic approach (Control)
Number of subjects: 35
Study: 11774104

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg/d for 8 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 45

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study: 31056482

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Conventional laparoscopic cholecystectomy (LC)
Number of subjects: 91
Study: 30485325

Group type: EXPERIMENTAL
Intervention: Dengue immunoglobulin G titres in children with prior medical diagnosis of dengue infection
Number of subjects: 865

Group type: COMPARATOR
Intervention: Dengue immunoglobulin G titres in children without prior medical diagnosis of dengue infection
Number of subjects: 865

Group type: EXPERIMENTAL
Intervention: Dengue immunoglobulin G levels above the median value
Number of subjects: 865